Cardiovascular Disease and Risk Factors in PCOS Women of Postmenopausal Age: A 21-Year Controlled Follow-Up Study
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is associated with the metabolic syndrome and, consequently, with a potentially increased risk of cardiovascular disease (CVD) and related mortality later in life. Studies regarding CVD and mortality in PCOS women well into the postmenopausal age are lacking. OBJECTIVE: Our objective was to examine whether postmenopausal PCOS women differ from controls regarding cardiovascular risk factors, myocardial infarction (MI), stroke and mortality. DESIGN AND SETTING: We conducted, at a university hospital, a prospective study of 35 PCOS women (61-79 yr) and 120 age-matched controls. The study was performed 21 yr after the initial study. PARTICIPANTS: Twenty-five PCOS women (Rotterdam criteria) and 68 controls participated in all examinations. Data on morbidity were based on 32 of 34 PCOS women and on 95 of 119 controls. INTERVENTIONS: INTERVENTIONS included reexamination, interviews, and data from the National Board of Health and Welfare and from the Hospital Discharge Registry. MAIN OUTCOME MEASURES: Blood pressure, glucose, insulin, triglycerides, total cholesterol, high- and low-density lipoprotein, apolipoprotein A1 and B, fibrinogen, and plasminogen activator inhibitor antigen were studied. Incidences of MI, stroke, hypertension, diabetes, cancer, cause of death, and age at death were recorded. RESULTS: PCOS women had a higher prevalence of hypertension (P = 0.008) and higher triglyceride levels (P = 0.012) than controls. MI, stroke, diabetes, cancer, and mortality prevalence was similar in the two cohorts with similar body mass index. CONCLUSIONS: The well-described cardiovascular/metabolic risk profile in pre- and perimenopausal PCOS women does not entail an evident increase in cardiovascular events during the postmenopausal period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PCOS is linked with increased prevalence of cardiometabolic risk factors, including dyslipidemia [10,11,12,13], hypertension [13,14,15], chronic inflammation, and impaired glucose tolerance [16,17], as well as overweight and obesity [18,19].”
From Moving beyond Weight: A Narrative Review of the Dietary and Lifestyle Management for Reducing Cardiometabolic Risk in Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [13]
In the citing paper
“Women with PCOS experience increased cardiometabolic risk—including the metabolic syndrome, hypertension, insulin resistance, obesity and dyslipidemia—predisposing them to increased risk for diabetes and cardiovascular disease (CVD).2,10,17, 18, 19, 20”
From Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort (2024) · cites this paper as [20]
In the citing paper
“The results regarding prevalence of T2DM in women with PCOS over the age of 40 years are conflicting.”
From Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution (2020) · cites this paper as Schmidt et al., 2011
In the citing paper
“The lack of significance might be due to the similar BMI between groups in that study and the fact that controls caught up in WHR during the 21-year follow-up period (Schmidt et al., 2011).”
From Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution (2020) · cites this paper as Schmidt et al., 2011
In the citing paper
“In our previous study of another cohort of women with PCOS and controls, where the women had a mean age of 72 years and similar BMI, the prevalence of T2DM was 22% for women with PCOS compared with 14% for controls (not statistically significant) (Schmidt et al., 2011).”
From Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution (2020) · cites this paper as Schmidt et al., 2011
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedGrundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760 · cited 1×
“risk of diabetes mellitus, cardiovascular disease (CVD) (13) and all-cause mortality (14).”
BackgroundGerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens
Clauss, A. (1957) · Acta Haematologica · doi:10.1159/000205234 · Cited by 3,208
Men at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 2×
“Diabetes, a strong risk factor for CVD, as well as insulin resistance and hyperinsulinemia are common among PCOS women of premenopausal (2, 4) and perimenopausal/early postmenopausal age (9, 17).”
BackgroundWalldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,229
Cited by
Items 201–267 of 267
Noroozzadeh, M., Raoufy, M. R., Yarandi, R. B., Shahrivar, F. F., Moghimi, N., & Tehrani, F. R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118394 · Cited by 3
The Long-Term Health Consequences of Polycystic Ovary Syndrome
Owens, L. A., & Franks, S. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108989831.018 · Cited by 2
Association between infertility and risk of cardiovascular diseases in young women
Ganjare, R., & Mangalaram, A. V. (2024) · F1000Research · doi:10.12688/f1000research.146939.1 · Cited by 2
Importance of the interdisciplinary, evidence-based diagnosis of polycystic ovary syndrome
Gődény, S., & Csenteri, O. K. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.29941 · Cited by 2
Sharma, P., Gupta, A., & Purohit, P. (2015) · Journal of Cardiovascular Disease Research · doi:10.5530/jcdr.2015.2.4 · Cited by 2
Reproduction and Metabolism: Insights from Polycystic Ovary Syndrome
Jasti, P., & Dunaif, A. E. (2012) · Endocrinology and Metabolism · doi:10.3803/enm.2012.27.3.180 · Cited by 2
Possible Role of Nrf2 in Oxidative and Inflammatory Processes During Menopause
Mendoza, C. C. C., Zamarripa, C. A. J., Ocharan-Hernández, M. E., & Iglesias, G. G. (2016) · InTech eBooks · doi:10.5772/65244 · Cited by 2
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2014) · The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy · doi:10.18370/2309-4117.2014.20.22-35 · Cited by 2
Effects of Acupuncture Treatment on Polycystic Ovary Syndrome (PCOS)
Ramanathan, G. (2023) · Obstetrics and gynecology. · doi:10.5772/intechopen.113799 · Cited by 2
Livadas, S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02051 · Cited by 2
The diagnostic and prognostic role of proteomics and metabolomics in Polycystic Ovary Syndrome
Khan, G. H. (2018) · Nottingham ePrints (University of Nottingham) · Cited by 2
Mani, H. (2014) · Figshare · Cited by 2
Herbert, S., Squires, A. P., Gilligan, C., & Woolf, K. (2026) · Women s Health · doi:10.1177/17455057251414294 · Cited by 1
“5,6 Additionally, individuals with PCOS present with higher prevalence of cardiometabolic risk factors, including dyslipidemia, 7–10 hypertension, 10–12 chronic inflammation, impaired glucose tolerance, 13,14 as well as overweight and obesity.”
Increased mortality in polycystic ovary syndrome— a cohort study
Piltonen, T., Koskenkari, N. V. S., Koivuaho, E., Morin-Papunen, L. C., Hurskainen, E., Gissler, M., Arffman, R. K., & Ollila, M. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag080 · Cited by 1
Polycystic ovary syndrome and breast cancer risk: a systematic review
Costanzi, F., Palomba, S., Seminara, G., Besharat, A. R., & Caserta, D. (2026) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2026.115248 · Cited by 1
Синдром поликистозных яичников. Официальное заявление Европейского общества эндокринологии
Conway, G. S., Dewailly, D., & Diamanti‐Kandarakis, E. (2015) · The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy · doi:10.18370/2309-4117.2015.25.32-52 · Cited by 1
Metabolic Aspects of Polycystic Ovary Syndrome
Dhesi, A. S., & Morelli, S. S. (2015) · Postgraduate Obstetrics & Gynecology · doi:10.1097/01.pgo.0000471433.43201.11 · Cited by 1
PCOS: Implications of Cardiometabolic Dysfunction
Fauser, B. C. J. M. (2017) · ISGE series · doi:10.1007/978-3-319-63540-8_10 · Cited by 1
Polycystic Ovary Syndrome-Related Risks in Postmenopausal Women
Anagnostis, P. G., Paschou, S. Α., Lambrinoudaki, I. V., & Goulis, D. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-13936-0_16 · Cited by 1
Stracquadanio, M., & Ciotta, L. (2015) · Springer eBooks · doi:10.1007/978-3-319-16760-2_3 · Cited by 1
Modern approaches to diagnostics of hyperandrogenism distributed forms in reproductive aged women
Бурка, О. А., Бобрик, М. И., Reznichenko, V. M., & Tutchenko, T. М. (2019) · Reproductive Endocrinology · doi:10.18370/2309-4117.2019.47.35-42 · Cited by 1
Primary Prevention and Cardiovascular Risk Assessment in Women
Peterson, L.-A., Freaney, P. M., & Gulati, M. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_10 · Cited by 1
Gairola, N., Chitme, H., & Sircar, R. (2024) · Indian Journal of Experimental Biology · doi:10.56042/ijeb.v62i03.1910 · Cited by 1
Polycystic ovary syndrome: from phenotype to genetype
Louwers, Y. V. (2014) · RePub (Erasmus University Rotterdam) · Cited by 1
Risco de Farmingham e evento cardiovascular em mulheres com síndrome dos ovários policísticos
Santos, A. G. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Aye, M. M. (2013) · Repository@Hull (Worktribe) (University of Hull) · Cited by 1
Cardiovascular risk in young women with Polycystic OvarySyndrome
Coulson, R.-M. K. (2014) · ORCA Online Research @Cardiff (Cardiff University)
High Risk, High Stakes: Optimizing Cardiovascular Risk Assessment in Women
Levit, R. D., & WENGER, N. K. (2012) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-012-0221-9
“12 years showed no increased incidence of MI, stroke, diabetes, cancer, and mortality despite increased risk factors (HTN, dyslipidemia) [35].”
BackgroundUnravelling the link between insulin resistance and androgen excess
O’Reilly, M. (2015) · University of Birmingham Institutional Research Archive (University of Birmingham)
Impact of polycystic ovary syndrome on the course of the menopausal period
Stachowiak, G., Zając, A. E., & Pertyński, T. (2013) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2013.35073
“Według nich dobrze opisany profil ryzyka (sercowo-naczyniowego, metabolicznego) kobiet pre- i perimenopauzalnych z PCOS nie pociąga za sobą ewidentnego wzrostu liczby zdarzeń sercowo-naczyniowych w okresie pomenopauzalnym [18].”
BackgroundVásquez, A., & Ester, H. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Hamilton, A. (2014) · OhioLink ETD Center (Ohio Library and Information Network)
Polycystic Ovary Syndrome: Implications for Cardiovascular, Endometrial, and Breast Disease
Escobar-Morreale, H. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95859-8
Lansdown, A. (2016) · ORCA Online Research @Cardiff (Cardiff University)
Non-Hemodynamic Components of EVA
Lambrinoudaki, I. V. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801387-8.00018-1
Hiperandrogenizm u kobiet po menopauzie
Kłosowski, P., Świątkowska−Stodulska, R., Berlińska, A., & Sworczak, K. (2017) · Forum Medycyny Rodzinnej
PCOS and Cardiometabolic Health over the Reproductive Years
Kakoly, N. S. (2019) · Figshare · doi:10.26180/5d194e6c84ad5
Rojas, J., Chávez-Castillo, M., Olivar, L. C., & Bermúdez, V. (2013) · Revista Latinoamericana de Hipertensión/Revista Latinoamericana de Hipertensiòn
Long-term health in women of age more than 40 years with polycystic ovary syndrome
Armeni, E., & Lambrinoudaki, I. V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00003-1
Endometrial Cancer and Precancer in Polycystic Ovary Syndrome
Marcus, E. A., Haines, K. E., & Gressel, G. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_21
Polycystic Ovary Syndrome: From in utero to Menopause
(2015) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jsafog-7-2-v
Meikle, A. W. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.03.019
Incidental findings on coronary computed tomography in women with selected reproductive disorders
van der Ham, K., van Zwol‐Janssens, C., Velthuis, B. K., Koster, M. P. H., Louwers, Y. V., Goei, D., Blomjous, M. S. H., Franx, A., Fauser, B. C. J. M., Boersma, E. H., et al. (2022) · Insights into Imaging · doi:10.1186/s13244-022-01238-z
Polycystic Ovarian Syndrome; A Clinician’s Perspective
Lindenberg, S. (2021) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2021.15.002064
Areloegbe, S. E. J., Peter, M. U., Oniyide, A. A., Akintayo, C. O., Fafure, A. A., Oyeleke, M. B., Ajadi, I. O., Amusa, O. A., Aturamu, A., & Olaniyi, K. S. (2022) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2022.100123
Wu, H., Fan, L., Sun, L., Wang, H., Liu, M., Sun, X., & Zhang, W. (2026) · Clinical and Experimental Obstetrics & Gynecology · doi:10.21203/rs.3.rs-3151344/v1
Hp, Z. (2014) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Nonhemodynamic Components of EVA: Polycystic Ovary Syndrome (PCOS)
Lambrinoudaki, I. V., & Armeni, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00004-0
Evaluation of polycystic ovary syndrome pharmacotherapy
Mária, K., Nikola, Z., Dana, M., Kolesár, D., & Zuzana, M. (2024) · Česká a slovenská farmacie · doi:10.36290/csf.2024.031
Loucks, T. L. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Amiri, M., Ramezani Tehrani, F., Behboudi‐Gandevani, S., Bidhendi-Yarandi, R., & Carmina, E. (2020) · Figshare · doi:10.6084/m9.figshare.11998881
Polycystic Ovaries and Effects of Hormones: An Observational Study in Females of Southern Assam
Das, N., Das, N., Kundu, S., Deb, M., Gupta, D. D., Haldar, S., & Gupta, S. D. (2024) · International Journal of Pharmaceutical and Clinical Research · doi:10.5281/zenodo.10891405
Sex hormones, type 2 diabetes mellitus, and chronic kidney disease
Lau Hui Ying, L. (2023) · doi:10.5282/edoc.32804
Τοκαμάνη, Μ. (2019) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.7356
Obermayer, S. M. (2015) · Unipub UB Graz (Universität Graz)
Cunha, K. D. D. (2012) · Lume (Universidade Federal do Rio Grande do Sul)
Farland, L. V., Degnan, W. J., Wang, S., Gaskins, A. J., Chavarro, J. E., Rich-Edwards, J. W., & Missmer, S. A. (2026) · Journal of Women s Health · doi:10.1177/15409996251414608
Metabolic aspects of polycystic ovary syndrome
Pappas, D., Kandaraki, E., Kalogirou, A., & Diamanti‐Kandarakis, E. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2656240
Herbert, S., Squires, A. P., Gilligan, C., & Woolf, K. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156433
Al-Shboul, Q. M., Sendall, M. C., O’Hara, L., Syed, M. A., Al-Jayyousi, G. F., & Hassan, D. A. (2026) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580261448474
Minato, S., Yamamoto, Y., Noguchi, H., Arata, M., Tamura, K., Aoki, H., Takeda, A., Takahashi, A., Purevdorj, T., Shinohara, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176710
“For example, Falcetta et al. [34] found that HDL-C levels were lower in women with PMOS aged <20 years than in those aged 21–30 years, and other studies with longer follow-up periods (>20 years) until postmenopausal age have reported age-related decreases in HDL-C [13,35].”
Murawski, M., Góral, A., Miszczak, M. M., & Prescha, A. (2026) · Nutrients · doi:10.3390/nu18193218
“…that these metabolic abnormalities should be considered as integral components of the syndrome rather than merely associated comorbidities, contributing to both reproductive dysfunction and long-term cardiometabolic health consequences that may persist beyond the menopausal transition [13–15].”
Abdul-Hassan, A. S. A. I. A. (2023) · Iraqi journal of biotechnology
Polycystic ovary syndrome - morphologic and dynamic evaluation by magnetic resonance imaging
Leonhardt, H. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Mazza, A. D. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.09.113
З., З. Я. (2017) · Medical alphabet
Metadata
- Authors
- Schmidt, J., Landin-Wilhelmsen, K., Brännström, M., & Dahlgren, E.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Schmidt, Johanna
- ORCID
- Brännström, Mats
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-12
- Volume
- 96
- Issue
- 12
- Pages
- 3794-3803
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2166647497
- Cited by
- 241
- References
- 44
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 11 · 2023: 22 · 2022: 24 · 2021: 16 · 2020: 17 · 2019: 14 · 2018: 15 · 2017: 18 · 2016: 11 · 2015: 21 · 2014: 26 · 2013: 13 · 2012: 14
- FWCI
- 19.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Västra Götalandsregionen
- Vetenskapsrådet
- Sahlgrenska Universitetssjukhuset
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- polycystic ovary syndrome, postmenopausal women, cardiovascular disease, cardiovascular risk factors, hypertension, triglycerides, myocardial infarction, stroke, mortality, metabolic syndrome, long-term follow-up
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Cholesterol, Female, Follow-Up Studies, Humans, Insulin, Middle Aged, Polycystic Ovary Syndrome, Registries, Risk Factors, Triglycerides, Incidence, Prevalence, Postmenopause
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.